Mutz Christopher 4
4 · ANI PHARMACEUTICALS INC · Filed Mar 13, 2026
Research Summary
AI-generated summary of this filing
ANI Pharmaceuticals (ANIP) Head of Rare Disease Christopher Mutz Sells 3,162 Shares
What Happened
Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals (ANIP), sold 3,162 shares on March 13, 2026. The shares were disposed for a total of approximately $226,526; the filing reports a weighted average sale price of $71.64 per share. This was a sale (not a purchase), which is commonly a routine liquidity event rather than a direct signal of company outlook.
Key Details
- Transaction date: March 13, 2026.
- Trade type: Sale (open market/private sale).
- Shares sold: 3,162; weighted average price: $71.64; total proceeds ≈ $226,526.
- Price range: trades executed between $70.27 and $72.62 (weighted average reported).
- Footnote: Sales were made under a Rule 10b5-1 trading plan adopted June 16, 2025.
- Shares owned after the transaction: Not specified in the provided filing.
- Filing timeliness: Form filed March 13, 2026 (no late filing indicated in the provided data).
Context
Sales made under a pre-established 10b5-1 trading plan are scheduled trades that can help insiders avoid accusations of trading on material nonpublic information. For retail investors, purchases generally carry more weight as potential positive signals; routine insider sales like this typically reflect personal liquidity or pre-planned selling rather than a change in company fundamentals.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-13$71.64/sh−3,162$226,526→ 91,309 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
- [F2]The shares were sold in multiple trades at prices ranging from $70.27 to $72.62. The price reported above reflects the weighted average sales price.